Evidence map›Paper›PMID 38800535›Full record

ArticleContemporary oncology (Poznan, Poland)2024

High tumour-infiltrating lymphocytes correlate with distinct gene expression profile and favourable survival in single hormone receptor-positive breast cancer.

Aleksandra Ciarka, Michał Kunc, Marta Popęda, Aleksandra Łacko, Barbara Radecka, Marcin Braun, Joanna Pikiel, Maria Litwiniuk, Katarzyna Pogoda, Ewa Iżycka-Świeszewska and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Contemporary oncology (Poznan, Poland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Aleksandra CiarkaDepartment of Pathology, Medical University of Gdańsk, Gdańsk, Poland.
Michał KuncDepartment of Pathology, Medical University of Gdańsk, Gdańsk, Poland.
Marta PopędaDepartment of Pathology, Medical University of Gdańsk, Gdańsk, Poland.
Aleksandra ŁackoDepartment of Oncology, Wrocław Medical University, Wrocław, Poland.
Barbara RadeckaDepartment of Oncology, Institute of Medical Sciences, University of Opole, Opole, Poland.
Marcin BraunDepartment of Pathology, Chair of Oncology, Medical University of Łódź, Łódź, Poland.
Joanna PikielDepartment of Oncology, Morski Hospital, Gdynia, Poland.
Maria LitwiniukDepartment of Clinical Oncology, Greater Poland Cancer Centre, Poznań, Poland.
Katarzyna PogodaDepartment of Breast Cancer and Reconstructive Surgery, Maria Sklodowska Curie National Research Institute of Oncology, Warsaw, Poland.
Ewa Iżycka-ŚwieszewskaDepartment of Pathology and Neuropathology, Medical University of Gdańsk, Gdańsk, Poland.
Anna ZellerLaboratory of Translational Oncology, Intercollegiate Faculty of Biotechnology, Medical University of Gdańsk, Gdańsk, Poland.
Magdalena NiemiraLaboratory of Translational Oncology, Intercollegiate Faculty of Biotechnology, Medical University of Gdańsk, Gdańsk, Poland.
Rafał PęksaDepartment of Pathology, Medical University of Gdańsk, Gdańsk, Poland.
Wojciech BiernatDepartment of Pathology, Medical University of Gdańsk, Gdańsk, Poland.
Elżbieta SenkusDepartment of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: This study aimed to evaluate the impact of tumour-infiltrating lymphocytes (TILs) on the expression of immune-related genes and prognosis in single hormone receptor-positive breast cancer. Material and methods: Tumour-infiltrating lymphocytes were analysed according to the guidelines of the International TILs Working Group in a cohort of 206 patients with single hormone receptor-positive breast cancer. Of these, 44.7% were classified as ER+/PgR-/HER2-, 18.4% as ER+/PgR-/HER2+, 26.2% as ER-/PgR+/HER2-, and 10.7% as ER-/PgR+/HER2+. Moreover, in 52 samples the analysis of gene expression profiling was performed using nCounter technology. Results: Most cases (74.3%) showed at least 1% of stromal TILs, with a median of 4%, mean of 16.3%, and interquartile range of 0-20%. ER-/PgR+ tumours displayed significantly higher TILs density than ER+/PgR- cases (p < 0.001, Wilcoxon test), regardless of HER2 status. The abundance of TILs was positively associated with ER-/PgR+ phenotype, higher Ki-67, and higher grade, but not with age, tumour size, or regional and distant metastases at diagnosis. Additionally, in ER+/PgR- subgroup higher TILs were associated with HER2-positive status. Stromal TILs > 5% were associated with better survival in the whole group, but this effect was less prominent in ER-/PgR+ patients. We identified 50 differentially expressed genes (DEGs) between single hormone receptor-positive breast tumours with high and low TILs, including 39 up-regulated and 11 down-regulated genes in the high TILs group. Conclusions: The up-regulated expression of immune-related genes was consistent also among separately analysed single hormone receptor-positive groups (ER+/PgR- and ER-/PgR+).

Indexed as

breast cancergene expressionprognosistumour infiltrating lymphocytes

Identifiers

PMID38800535
PMCPMC11117162

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.